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collateral vessels. Pathologic changes in the bowel that are
associated with mesenteric venous thrombosis — especial-
ly bowel dilatation, bowel-wall thickening, reduced motil-
ity, and intestinal pneumatosis — can be assessed as readily
by ultrasonography as by CT.
After the diagnosis of mesenteric venous thrombosis,
frequent monitoring should be conducted by ultrasonog-
raphy in order to avoid radiation exposure or contrast-
induced damage.1
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To the Editor: In their review of mesenteric venous
thrombosis, Kumar et al. could have added that the results
of a D-dimer assay can help establish the diagnosis.
DONALD N. COHEN, M.D.
Northern Westchester Hospital
Mount Kisco, NY 10549
cohend@pol.net
The authors reply:
To the Editor: Thrombolytic therapy may be beneficial
in patients with localized thrombus, especially if there is
worsening bowel ischemia without obvious necrosis. Strate-
gies include the systemic infusion of thrombolytic agents,1
percutaneous transhepatic or transjugular infusion of throm-
bolytic agents directly into the thrombus,2 the infusion of
such agents into the superior mesenteric artery,3 and me-
chanical thrombectomy.4 However, reports of success should
be interpreted with caution. Many of the reports have in-
volved patients with thrombosis in the portal vein or in the
superior mesenteric vein at its junction with the portal vein.
In our experience, these patients are not likely to require sur-
gical intervention, and most of them can be treated with an-
ticoagulation and supportive measures alone. Many of the
reports cited by the correspondents involve patients who did
not require surgery and who may have done well with anti-
coagulation alone. Although a transjugular intrahepatic shunt
has the potential advantage of allowing easy access to the
mesenteric venous circulation, a high rate of stenosis and the
permanence of the procedure argue against its use. Current
consensus recommendations for the use of transjugular in-
trahepatic shunts do not include mesenteric venous throm-
bosis as an indication.5
We agree with Stadler et al. that transabdominal color
Doppler ultrasonography may allow diagnosis of mesenteric
venous thrombosis. However, ultrasonography is very much
an operator-dependent technique, and the results are less
reproducible than those of CT. Patients with acute mesen-
teric venous thrombosis often have ileus, gaseous disten-
tion, and abdominal tenderness, all of which preclude an
adequate examination. CT should be the diagnostic test of
choice for several reasons. In addition to allowing diagnosis
of mesenteric venous thrombosis and visualization of the
thrombus, CT permits complete examination of the struc-
ture of the bowel, the detection of potential complications
such as bowel ischemia and perforation, and the identifica-
tion of potential precipitating causes of the thrombosis. 
In response to Dr. Cohen: an increase in the D-dimer
level is not specific enough to diagnose mesenteric venous
thrombosis.
SHAJI KUMAR, M.D.
MICHAEL G. SARR, M.D.
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Severe Hyperosmolar Metabolic Acidosis Due 
to a Large Dose of Intravenous Lorazepam
To the Editor: In a 34-year-old woman with a history of
alcohol abuse, cardiomyopathy, and AIDS, acute respira-
tory failure developed as a result of Escherichia coli sepsis
and pneumonia. Initial laboratory studies revealed a pH of
7.2, a bicarbonate level of 8.8 mmol per liter, a partial
pressure of carbon dioxide of 26 mm Hg, an anion gap of
15.4 mmol per liter, a lactate level of 6.9 mmol per liter,
and a creatinine level of 1.8 mg per deciliter, with a normal
blood sugar level and no ketones.
After four days of treatment, the patient’s acidosis was
worse (pH, 6.9; bicarbonate level, 6.2 mmol per liter; an-
ion gap, 17.8 mmol per liter), despite a slow improvement
in the lactate level (to 4.5 mmol per liter). The serum os-
molality was 462 mOsm per liter with an osmolal gap of
165 mOsm per liter. Standard blood tests for methanol,
ethylene glycol, and isopropyl alcohol were negative. It was
noted that the woman was being sedated with increasing
doses of intravenous lorazepam (up to 30 mg per hour),
which contained 0.18 ml of polyethylene glycol–400
(PEG-400) in propylene glycol with 2 percent benzyl alco-
hol per 2-mg vial. She had received 1696 mg of lorazepam
in 78 hours, for a cumulative PEG-400 dose of 153 ml. De-
spite treatment with fomepizole, a polyethylene glycol an-
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tagonist that is administered intravenously, she required he-
modialysis. After three hemodialysis sessions, the patient’s
pH and bicarbonate level had improved (7.37 and 26 mmol
per liter, respectively), and her osmolal gap had decreased
to 40 mOsm per liter. She was discharged after 26 days in
the hospital. Her renal function was stable; the creatinine
level was 1.7 mg per deciliter. It should be noted that our
laboratory was unable to quantify the levels of PEG-400, its
metabolites, or benzyl alcohol.
Polyethylene glycol is oxidized by alcohol dehydrogen-
ase to hydroxy acid and diacid metabolites, possibly con-
tributing to the development of metabolic acidosis.1 In
previous reports polyethylene glycol has been implicated
in hyperosmolar states,2,3 acute renal failure,3-5 and mild
metabolic acidosis3,4 due to the topical or intravenous use
of various drugs, including lorazepam.5 Although our pa-
tient had preexisting metabolic anion-gap acidosis, we be-
lieve that the large dose of intravenous lorazepam that she
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The Popliteal-Artery Entrapment Syndrome 
in a Patient Using Anabolic Steroids
To the Editor: The popliteal-artery entrapment syndrome
is a potentially serious but rare cause of ischemia of the
legs.1 It occurs predominantly in young persons and is due
to an abnormal anatomical relation between the popliteal
artery and the tendinous insertion of the gastrocnemius
muscle. Usually, symptoms arise when there is occlusion of
the functional artery during contraction of the calf muscle;
arterial thrombosis is a rare cause.2 Abuse of anabolic ster-
oids has increased in frequency during the past decade and
is associated with a documented risk of acute coronary-artery
and peripheral-artery thrombosis.3-5 We describe the occur-
rence of thrombotic occlusion of the popliteal artery in an
athlete with the popliteal-artery entrapment syndrome who
abused anabolic steroids.
A 31-year-old male bodybuilder was referred to our emer-
gency department with a three-day history of claudication
and paresthesias of the left foot. Clinical examination re-
vealed symmetric muscular hypertrophy of the legs, with
discoloration of the left foot and decreased skin temperature
below the left knee. The left popliteal, tibialis, and dorsalis
Figure 1. Angiograms of the Left Leg before Thrombolysis, Showing Complete Occlusion of the Pop-
liteal Artery (Panel A), and after Thrombolysis, Showing Restored Patency (Panel B).
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